GRFS - グリフォルス （Grifols S.A.） グリフォルス

Futures Flat Ahead Of CPI Data US stock futures traded in a very tight range on Wednesday as investors held off on making big trades ahead of today''s CPI print which is expected to provide clues on the Federal Reserve’s outlook for rate hikes. Contracts on the S&P 500 were up 0.2% at 7:45am ET while Nasdaq futures were fractionally in the red. The Bloomberg Dollar Spot Index was little changed, as Treasury yields edged higher across the curve, mirroring moves in European bond markets. Oil and gold rose. Bitcoin was flat after a four-day gain, its longest streak in three weeks. Among notable movers in premarket trading, Bed Bath & Beyond climbed 2.6% after the troubled retailer raised $48.5 million through a share sale as it seeks cash to avert bankruptcy. Nutex Health jumped as much as 34% after the health care management company said that it has entered into a $100 million pre-paid advance agreement with Yorkville Advisors Global. Here are some other notable premarket movers: MongoDB (shares rise 3.4%, while Confluent gains 4.8%, after both are upgraded to overweight from equal-weight at Morgan Stanley, as the broker expects faster and increased expenditure on the transition of companies to the public cloud.

Grifols (GRFS) (GIKLY) said it entered a research, development and sublicense agreement with Selagine for developing and selling immunoglobulin eye drops for dry eye disease

https://www.investing.com/news/assorted/grifols-collaborates-with-selagine-for-development-and-commercialization-of-immunoglobulin-eye-drops-for-treating-dry-eye-disease-432SI-3022785

CHICAGO, March 6, 2023 /PRNewswire/ -- Selagine, Inc., a spin-out company from the University of Illinois at Chicago (UIC), announced today that it has entered into a research, development and sublicense agreement with Grifols (Nasdaq: GRFS), a global leader in plasma-derived medicines,…

Grifols (GRFS) traded lower Friday after Morgan Stanley downgraded the plasma-focused biotech, arguing that its FY22 results indicated slower margin recovery. Read the full story here.

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Aim Immunotech, Altamira, Aurinia, Bausch Health, Bharat, Biocytogen, Brii, Dompé, Excellgene, Gigagen, Grifols, Icosavax, Intas, Liberothera, Moderna, Oyagen, Prestige, Rona, Sandoz, Sanofi, Sun, Sunshine, Teva, Therapeutic Solutions International, Tonix.

Grifols delivered a mixed quarter on the financial results. Read more to find out why we are still on with our long-term thesis on GRFS stock.

If history is any guide, there may be good fortune ahead for shares of Grifols (NASDAQ: GRFS ). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock. What To Know: Many traders use moving average crossover systems to make their decisions. When a shorter-term average price crosses above a longer-term average price, it could mean the stock is trending higher. … Full story available on Benzinga.com

Stocks, Cryptos Tumble To Close Out Catastrophic First-Half It was supposed to be a 7% ramp into month-end on billions in pension fund residual buying. Instead, it ended up being more or less the opposite, with crypto-led liquidations dragging futures and global markets lower, and extending Wednesday losses after central bankers issued warnings on inflation and fueled concern that aggressive policy will end with a hard-landing recession, which increasingly more now see as being 2022 business, an outcome that now appears assured especially after yesterday''s disastrous guidance cut from RH , the second in three weeks! Recession fears and inflation woes may be prolonged by today''s PCE deflator report. The consumer price gauge favored by the Fed may have picked up to 6.4% last month from 6.3%. Personal income growth probably edged up but Bloomberg Economics highlights an anticipated decline in real personal spending as a major worry. Meanwhile, China’s economy showed further signs of improvement in June with a strong pickup in services and construction, even if the latest Chinese PMI print came slightly below expectations.

BARCELONA (Reuters) – Spanish pharmaceuticals company Grifols is not analysing any increase in share capital for the timebeing, Grifols’ vice president told investors on Thursday, according to a market source.

Major players in the blood group typing market are Grifols, Bio-Rad Laboratories, Immucor Inc, Ortho Clinical Diagnostics, Quotient, BAG Health Care GmbH, AXO Science, Agena Bioscience, Merck KGaA, and Beckman Coulter Inc. Major players in the blood group typing market are Grifols, Bio-Rad Laboratories, Immucor Inc, Ortho Clinical Diagnostics, Quotient, BAG Health Care GmbH, AXO Science, Agena Bioscience, Merck KGaA, and Beckman Coulter Inc.

Major players in the immunochemistry diagnostic devices and equipment market are Abbott Diagnostics, Roche Diagnostics, Siemens Healthcare Diagnostics, Diamond Diagnostics, Dynex Technologies, Grifols, Hycor Biomedical, Immunodiagnostic Systems, Inova Diagnostics, and LabCorp. Major players in the immunochemistry diagnostic devices and equipment market are Abbott Diagnostics, Roche Diagnostics, Siemens Healthcare Diagnostics, Diamond Diagnostics, Dynex Technologies, Grifols, Hycor Biomedical, Immunodiagnostic Systems, Inova Diagnostics, and LabCorp.

We are confident on Grifols'' ability to navigate the short-term downgrade. Biotest acquisition completed, now is time to deliver. See more on GRFS stock here.

Bloodbath: Futures, Yuan Tumble as 10Y Yields Soar On Global Stagflation Fears It''s a bloodbath. With Bank of America conveniently reminding us over the weekend that markets never bottom on a Friday, and that Mondays tend to be the worst day of the week for markets… ... that''s exactly what is playing out today as risk assets are puking across the globe, with S&P 500 futures crashing, the Chinese yuan tumbling amid a growing slowdown in China, and the US 10-year Treasury yield climbing as high as 3.2% as risk parity funds are getting monkeyhammered... again. A slide in US stock futures set up Wall Street’s main indexes to extend weeks of declines on concerns of a recession amid monetary tightening and surging inflation. Contracts on the S&P 500 fell 2.1% as of 7:15 a.m. in New York, trading at session lows, as the MSCI gauge of world stocks extended its retreat from a November peak to 16% as a wave of risk aversion continues to sweep through global markets after Friday’s U.S. jobs data left little room for a change of course in the Fed’s rate-increase and quantitative-tightening plans.

Spanish biotech Grifols (GRFS) stock fell ~8% May 9 on Spain''s stock exchange BME, where it trades under the symbol GRF, giving up most of the gains following its Q1 results on May…